Sie sind auf Seite 1von 1

Table 7.

15 WHO definitions of clinical, immunological and virological


failure for the decision to switch ART regimens

Failure Definition Comments

Adults and adolescents


The condition must be
New or recurrent clinical event indicating
differentiated from immune
severe immunodeficiency (WHO clinical
reconstitution inflammatory
stage 4 condition) a after 6 months of
syndrome b occurring after
effective treatment
initiating ART
Clinical failure Children
For adults, certain WHO clinical
New or recurrent clinical event indicating stage 3 conditions (pulmonary TB
advanced or severe immunodefiency and severe bacterial infections)
(WHO clinical stage 3 and 4 clinical may also indicate treatment
condition with exception of TB) after 6 failure a
months of effective treatment

Without concomitant or recent


Adults and adolescents infection to cause a transient
CD4 count falls to the baseline (or decline in the CD4 cell count
below) A systematic review found
or that current WHO clinical and
immunological criteria have low
Persistent CD4 levels below sensitivity and positive predictive
100 cells/mm3 value for identifying individuals
Immunological
failure with virological failure (182) . The
Children predicted value would be expected
to be even lower with earlier ART
Younger than 5 years
initiation and treatment failure at
Persistent CD4 levels below 200 cells/mm3 higher CD4 cell counts. There is
or <10% currently no proposed alternative
definition of treatment failure and
Older than 5 years
no validated alternative definition
Persistent CD4 levels below 100 cells/mm3 of immunological failure

The optimal threshold for defining


virological failure and the need
for switching ART regimen has not
been determined
Plasma viral load above 1000 copies/
An individual must be taking ART
Virological ml based on two consecutive viral load
for at least 6 months before it can
failure measurements after 3 months, with
be determined that a regimen has
adherence support
failed
Assessment of viral load using DBS
and point-of-care technologies
should use a higher threshold

a
See the list of clinical conditions associated with advanced or severe HIV disease associated with immunodeficiency in Annex 1.
b
Section 6.1 discusses immune reconstitution inflammatory syndrome.

Das könnte Ihnen auch gefallen